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Purpose of the study
Durable virological suppression during HAART is associ-
ated with immunological recovery in patients with HIV
infection. Current guidelines recommend to initiate
HAART when CD4+ cell count falls <350/μl. However,
recent studies have shown a higher immune restoration
when HAART was started at CD4+ baseline level > 350
cells/μl. We retrospectively assessed the long-term immu-
nological outcome in patients with sustained virological
suppression during HAART, for up to 8 years.
Methods
HIV-infected consecutive patients attending to our clinic
were included, with the following inclusion criteria: fol-
low-up >1 year while on HAART and sustained virologic
suppression (HIV-RNA <400 copies/ml) for at least 6 con-
secutive months. We analyzed the immunological out-
come by of annual determination of: 1) CD4+ cell count;
and 2) change in CD4+ cell count from baseline. Com-
plete immunological recovery was defined as CD4+ cell
count ≥700/μl. Patients were stratified according to base-
line CD4+ cell (counts of <200/μl, 200–350/μl and >350/
μl), age, HIV risk group, HCV co-infection, HAART regi-
men, sex, and race. A statistical analysis was performed by
linear regression.
Summary of results
352 patients were observed: 172, 85 and 95 patients had
baseline CD4+ cell count <200/μl, 200–350/μl and >350/
μl, respectively. After 5 years of therapy, 29%, 69% and
82% of patients with baseline CD4+ cell count, respec-
tively, <200/μl, 200–350/μl and >350/μl, exceeded the
threshold of 500 cells/μl (p = 0.034).
Among patients with baseline CD4+ cell count >350/μl,
mean CD4+ cell count reached a plateau with a complete
immunological recovery by 4 years of suppressive HAART.
CD4+ cell count increased even after 8 years without ever
reaching a full immunological recovery in patients with
baseline CD4+ cell count <200/μl.
Patients aged ≥50 years had a slower but similar immune
recovery (p > 0.05). We found no significant differences in
immunological response according to baseline viral load,
HIV risk factor, sex, HCV co-infection and HAART regi-
men.
Conclusion
In our study, patients with sustained viral suppression
experienced a significant immune recovery over 8 years of
HAART. We found that complete immune recovery was
achieved only in patients with baseline CD4+ cell count
>350/μl. This observation strengthens the hypothesis that
starting HAART at CD4+ cell counts < 50/μl could not be
adequate to obtain a complete immunological recovery.
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